| No | Therapeutic Area & Product | Scheme | Indication | | | | | | | | | Cycle | | | | | | | | | | |
|----|--|-------------------------------------|--|------|------|------|------|------|------|------|------|-------|------|------|------|------|------|----------|--------|-----------------------------------|--|--|
| | * | Scheme | indication | | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 16 | 17 | 18 | | |
| A | Breast Cancer | T | T | | | | | | _ | | | | _ | _ | | | | | — | — | | |
| 1 | Herceptin Vials 600 MG/5 ML SC 1 RPAP | 2+1 | Adjuvant BC; Neoadjuvant BC; MBC | | | | | | Buy | | | | | | | | | Buy Fre | | | | |
| | Perjeta Vial 420mg/14 ml 1 RPAP | 2+1 | | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free Buy | / Buy | Free | | |
| 2 | Perjeta Vial 420mg/14 ml 1 RPAP (Loading dose at Cycle 1 only) | Free | 1L MBC | Free | | | , | | | , | | | | | | | | | — | | | |
| | Herceptin MD Vial 440mg/20ml 1 RPAP | Free | | Free | | | | | | | Free | Free | Free | Free | Free | Free | Free | Free Fre | ? Free | Buy Free Free Free Free Free Free | | |
| 3 | Perjeta Vial 420mg/14 ml 1 RPAP | Paid | | Buy | Buy | Free | Buy | Buy | Free |] | | | | | | | | | | | | |
| | Perjeta Vial 420mg/14 ml 1 RPAP (Loading dose at Cycle 1 only) | Free | Neo Adjuvant EBC | Free | | | _ | | | 1 | | | | | | | | | | | | |
| | Herceptin MD Vial 440mg/20ml 1 RPAP | Free | | Free | _ | _ | Free | _ | | | | | , | | | | | | — | | | |
| | Perjeta Vial 420mg/14 ml 1 RPAP | Paid | Adjuvant with node- | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free Buy | Buy | Free | | |
| 4 | Perjeta Vial 420mg/14 ml 1 RPAP (Loading dose at Cycle 1 only) | Free | positive disease | Free | | | | | | | | | | | | | | | | | | |
| | Herceptin MD Vial 440mg/20ml 1 RPAP | Free | poolaro diocaco | Free | Free | Free | Free | Free | Free | Free Fre | e Free | Free | | |
| 5 | Perjeta Vial 420mg/14 ml 1 RPAP | Paid | Adjuvant eBC after | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | | | | | | | |
| 5 | Herceptin MD Vial 440mg/20ml 1 RPAP | Free | neoadjuvant anti- HER2 | Free | Free | Free | Free | | | | | | | |
| | Kadcyla Vials 100mg 1 RPAP | 1+1 | 2L MBC or relapsed | Free | Buy | | | | | | | | | | | | | | | | | |
| | | 2+1 | from Trastuzumab treatment | | | Fre | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free Buy | Buy | Free | | |
| 6 | Kadcyla Vials 160mg 1 RPAP | 1+1 | Adjuvant eBC with residual disease after | Free | Buy | | | | | | | | | | | | | | | | | |
| | | 2+1 | anti-HER2 preoperative systemic therapy | | | Fre | Buy | Buy | Free | Buy | Buy | | | | | | | | | | | |
| 7 | Avastin 100 mg/4 ml RPAP | Cycle 1-9: 2+1 Cycle 10-17: 1+1 | Triple negative breast cancer (TNBC) | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | Buy | Free Buy | Free | ; | | |
| В | Lung Cancer | | | | | | | | | | | | | | | | | | | | | |
| | | 1+1 | 2L NSCLC after progress from chemo | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy Fre | Buy | Free | | |
| | | 1+1 | 2L NSCLC after progress from Avastin 1L ES-SCLC in combination with carboplatin and etoposide | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free Buy | Free | Buy | | |
| 1 | Tecentrig vials 1200mg/20mL IV 1 RPAP | Cycle 1-6: 2+1 Cycle 7-12: 1+1 | | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | Buy | Free | | | | | | | |
| | | 1+1 | 1L PD-L1 High Non- Small Cell Lung Cancer (NSCLC) monotherapy | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy Fre | Buy | Free | | |
| | | Cycle 1-6: 2+1 Cycle 7-12: 1+1 | platinum mÜC) | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | Buy | Free | | | | | | | |
| 2 | Tecentriq vials 1200mg/20mL IV 1 RPAP | Cycle 1-16: 1+1 | 1L Metastatic Nonsquamous NSCLC with no EGFR or ALK | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy Fre | 9 | | | |
| | Avastin 100 mg/4 ml RPAP | Cycle 1-8: 1+1, Cycle 9-16: free | Genomic Tumor Aberrations | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Free | Free | Free | Free | Free | Free Fre | Э | | | |

| 3 | Alecensa Caph 150mg 224 RPAP | Year1: 1+1, Year 2: 1+2, Year 3: 1+5 | NSCLC with ALK positive | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Free | Buy | Free I | Free |
|-----|---|---|---|----------|------|----------|------|------|------|------|------|----------|------|----------|------|------|------|------|---------------|---------------|-----------|
| 4 | Avastin 100 mg/4 ml RPAP | 2+1 & 1+1 | IL NSCLC EGFR Neg, ALK neg or unknown 2L NSCLC after | | | | Buy | | | | | | | | | | | | $\overline{}$ | | \exists |
| C | GI & GU | | progress with Tarceva, T790M neg | Free | Buy | Buy | Free | Buy | Free | Buy | Free | Buy | Free | | | | | | | | |
| C | di & do | Cycle 1-9: 2+1 | 1L MCRC - Bi-weekly | Dur | Dur | Euro | Buy | Dur | Eugo | Done | Dur | Eugo | Dur | Eugo | D | Eugo | Dur | Eugo | D.v. | Eugo | |
| , | Accepting 400 mm/4 and DDAD | Cycle 10-17: 1+1 | 1L MCRC - 3 weekly | | | | Buy | | | | | | | | | | | | | | \dashv |
| | Avastin 100 mg/4 ml RPAP | Cycle 1-6: 2+1 Cycle 7-10: 1+1 | 2L MCRC | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | | | | , | | | | \Box |
| | | | 1L MOC | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | | | | | | | Buy | Free |
| 2 | Avastin 100 mg/4 ml RPAP | 1+1 | - | <u> </u> | _ | <u> </u> | Free | | | _ | | <u> </u> | | <u> </u> | _ | | - | Buy | \rightarrow | Buy 1 | _ |
| 1 ~ | Trustin 100 mg 1 m Kt 11 | 111 | 2L MOC - biweekly | - | | | Free | | | | | | | _ | _ | | | | - | Buy | _ |
| D | LIVER | | Cervical Cancer | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | Free |
| D | LIVER | Cycle 1-9: 2+1 | l e | 1 | г - | Т | 1 | | | | | | | | | - | 1 | | $\overline{}$ | $\overline{}$ | - |
| 1 | Tecentriq vials 1200mg/20mL IV 1 RPAP | Cycle 10-25: 1+1 | Hepatocellular | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | Buy | Free | Buy | ₹ree |
| L' | Avastin 100 mg/4 ml RPAP | Cycle 1-9: 1+2 Cycle 10-25: free | Carcinoma (HCC) | Buy | Free | Free | Buy | Free | Free | Buy | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free l | ₹ree |
| E | HEMATOLOGY | | | | | | | | | | | | | | | | | | | | |
| | Gazyva Vial 1000mg/40ml 1 RPAP | Loading dose Cycle 1: Buy 2 vial + 1 Free vial; Maintenance Cycle 2-3: 1+1; Maintenance Cycle 4-6: 2+1 | Chronic Lymphocytic Leukaemia (CLL); previousely untreated; in combination with Chorambucil | 2+1 | Buy | Free | Buy | Buy | Free | | | | | | | | | | | | |
| 1 | | Loading dose Cycle 1: Buy 2 vial + 1 Free vial; Maintenance Cycle 2-10: 2+1; Maintenance Cycle 11-14: 1+1 | 1L Follicular Lymphoma (FL) | 2+1 | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Free | Buy | Free | | | | |
| 2 | Hemlibra Vial 30mg/1ml SC 1 RPAP Hemlibra Vial 60mg/0.4ml SC 1 RPAP Hemlibra Vial 105mg/0.7ml SC 1 RPAP | Loading Dose: 1+1 + 1 + 1 (*depend on body weight) | Hemophilia A with INHIBITOR; Hemophilia without Inhibitor | Buy | Free | Buy | Free | | | | | | | | | | | | | | |
| | Hemlibra Vial 150mg/1ml SC 1 RPAP | Maintenance: 2+1 | Without Hillibitor | | | | | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | Free | Buy | Buy | =ree | \Box | \Box |